216 related articles for article (PubMed ID: 19053977)
21. An analysis of the effect of mu-opioid receptor gene (OPRM1) promoter region DNA methylation on the response of naltrexone treatment of alcohol dependence.
Lin Y; Kranzler HR; Farrer LA; Xu H; Henderson DC; Zhang H
Pharmacogenomics J; 2020 Oct; 20(5):672-680. PubMed ID: 32029903
[TBL] [Abstract][Full Text] [Related]
22. The μ-opioid receptor and treatment response to naltrexone.
Thorsell A
Alcohol Alcohol; 2013; 48(4):402-8. PubMed ID: 23543091
[TBL] [Abstract][Full Text] [Related]
23. Population-specific effects of the Asn40Asp polymorphism at the mu-opioid receptor gene (OPRM1) on HPA-axis activation.
Hernandez-Avila CA; Covault J; Wand G; Zhang H; Gelernter J; Kranzler HR
Pharmacogenet Genomics; 2007 Dec; 17(12):1031-8. PubMed ID: 18004207
[TBL] [Abstract][Full Text] [Related]
24. Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans.
Arias AJ; Gelernter J; Gueorguieva R; Ralevski E; Petrakis IL
Am J Addict; 2014; 23(3):288-93. PubMed ID: 24724887
[TBL] [Abstract][Full Text] [Related]
25. Medication-enhanced behavior therapy for alcohol use disorder: Naltrexone, Alcoholics Anonymous Facilitation, and OPRM1 genetic variation.
Stewart SH; Walitzer KS; Blanco J; Swiatek D; Paine Hughes L; Quiñones-Lombraña A; Shyhalla K
J Subst Abuse Treat; 2019 Sep; 104():7-14. PubMed ID: 31370987
[TBL] [Abstract][Full Text] [Related]
26. The role of the Asn40Asp polymorphism of the mu opioid receptor gene (OPRM1) on alcoholism etiology and treatment: a critical review.
Ray LA; Barr CS; Blendy JA; Oslin D; Goldman D; Anton RF
Alcohol Clin Exp Res; 2012 Mar; 36(3):385-94. PubMed ID: 21895723
[TBL] [Abstract][Full Text] [Related]
27. Polymorphisms of the mu-opioid receptor and dopamine D4 receptor genes and subjective responses to alcohol in the natural environment.
Ray LA; Miranda R; Tidey JW; McGeary JE; MacKillop J; Gwaltney CJ; Rohsenow DJ; Swift RM; Monti PM
J Abnorm Psychol; 2010 Feb; 119(1):115-25. PubMed ID: 20141248
[TBL] [Abstract][Full Text] [Related]
28. Association of µ-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis.
Chamorro AJ; Marcos M; Mirón-Canelo JA; Pastor I; González-Sarmiento R; Laso FJ
Addict Biol; 2012 May; 17(3):505-12. PubMed ID: 22515274
[TBL] [Abstract][Full Text] [Related]
29. Influence of the OPRM1 A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone.
Setiawan E; Pihl RO; Benkelfat C; Leyton M
Pharmacogenomics; 2012 Jul; 13(10):1161-72. PubMed ID: 22909206
[TBL] [Abstract][Full Text] [Related]
30. Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status.
Schacht JP; Randall PK; Latham PK; Voronin KE; Book SW; Myrick H; Anton RF
Neuropsychopharmacology; 2017 Dec; 42(13):2640-2653. PubMed ID: 28409564
[TBL] [Abstract][Full Text] [Related]
31. COMBINE genetics study: the pharmacogenetics of alcoholism treatment response: genes and mechanisms.
Goldman D; Oroszi G; O'Malley S; Anton R
J Stud Alcohol Suppl; 2005 Jul; (15):56-64; discussion 33. PubMed ID: 16223057
[TBL] [Abstract][Full Text] [Related]
32. Suppression of alcohol preference by naltrexone in the rhesus macaque: a critical role of genetic variation at the micro-opioid receptor gene locus.
Barr CS; Chen SA; Schwandt ML; Lindell SG; Sun H; Suomi SJ; Heilig M
Biol Psychiatry; 2010 Jan; 67(1):78-80. PubMed ID: 19748082
[TBL] [Abstract][Full Text] [Related]
33. Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the mu-opioid receptor locus (OPRM1).
Hernandez-Avila CA; Wand G; Luo X; Gelernter J; Kranzler HR
Am J Med Genet B Neuropsychiatr Genet; 2003 Apr; 118B(1):60-5. PubMed ID: 12627468
[TBL] [Abstract][Full Text] [Related]
34. Questionable efficacy for naltrexone in patients with Asp40.
Mattes JA
Arch Gen Psychiatry; 2009 Jul; 66(7):796; author reply 796-7. PubMed ID: 19581571
[No Abstract] [Full Text] [Related]
35. Topiramate Versus Naltrexone for Alcohol Use Disorder: A Genotype-Stratified Double-Blind Randomized Controlled Trial.
Morley KC; Kranzler HR; Luquin N; Jamshidi N; Adams C; Montebello M; Tremonti C; Dali G; Logge W; Baillie A; Teesson M; Trent R; Haber PS
Am J Psychiatry; 2024 May; 181(5):403-411. PubMed ID: 38706338
[TBL] [Abstract][Full Text] [Related]
36. Association between two mu-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence.
Zhang H; Luo X; Kranzler HR; Lappalainen J; Yang BZ; Krupitsky E; Zvartau E; Gelernter J
Hum Mol Genet; 2006 Mar; 15(6):807-19. PubMed ID: 16476706
[TBL] [Abstract][Full Text] [Related]
37. Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in Alcohol Use Disorder: a randomized trial.
Schacht JP; Hoffman M; Chen BH; Anton RF
Pharmacogenomics J; 2022 Feb; 22(1):1-8. PubMed ID: 34381173
[TBL] [Abstract][Full Text] [Related]
38. Genetic moderators of naltrexone's effects on alcohol cue reactivity.
McGeary JE; Monti PM; Rohsenow DJ; Tidey J; Swift R; Miranda R
Alcohol Clin Exp Res; 2006 Aug; 30(8):1288-96. PubMed ID: 16899031
[TBL] [Abstract][Full Text] [Related]
39. Haplotypes at the OPRM1 locus are associated with susceptibility to substance dependence in European-Americans.
Luo X; Kranzler HR; Zhao H; Gelernter J
Am J Med Genet B Neuropsychiatr Genet; 2003 Jul; 120B(1):97-108. PubMed ID: 12815747
[TBL] [Abstract][Full Text] [Related]
40. Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis.
Arias A; Feinn R; Kranzler HR
Drug Alcohol Depend; 2006 Jul; 83(3):262-8. PubMed ID: 16387451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
